NInside the HG Care Hub™ · Version 1.0
HG Insights Dashboard™
Understanding Hyperemesis Gravidarum through data, research, and evidence.
"We cannot improve what we do not measure."
The HG Care Hub™ teaches. The HG Insights Dashboard™ measures, visualizes, and explains.
Together, they transform trusted evidence into meaningful insights that advance understanding, inform decisions, and strengthen the future of Hyperemesis Gravidarum care.
This platform brings together trusted public data and peer-reviewed research on Hyperemesis Gravidarum into one transparent picture—what we know, how well we know it, and where the evidence ends.
Every chart, statistic, and visualization is grounded in publicly available research and clearly cites its source, strength of evidence, and publication date.
Strong evidence
Moderate evidence
Limited evidence
Major evidence gap
HG By the Numbers
The state of what we know
Hover any figure for its full provenance. Updated quarterly from public sources.
HG prevalence
0.3–3%
of pregnancies meet HG clinical criteria; definitions vary across studies.
Source: Systematic reviews (published estimate)
Strength: Moderate · Confidence: Medium
Updated: July 2026
Pregnancies affected · U.S. / yr
≈11k–108k
Modeled: published prevalence × ~3.6M annual U.S. births. A range, not a count — HG has no surveillance category.
Source: CDC natality × published prevalence (modeled)
Strength: Moderate · Confidence: Medium
Updated: July 2026
Early-pregnancy hospitalization
Leading cause
HG is consistently reported among the most common reasons for hospital admission in the first half of pregnancy.
Source: AHRQ HCUP analyses; ACOG PB 189
Strength: Strong · Confidence: High
Updated: July 2026
ED utilization
Data pending
National ED-visit series awaits the HCUP NEDS connection. Published single-center studies exist; no national figure is shown until then.
Source: HCUP NEDS (planned)
Strength: Limited · Confidence: Low
Updated: July 2026
Active clinical trials
~30
Interventional and observational HG studies registered worldwide — small for a condition this burdensome.
Source: ClinicalTrials.gov / WHO ICTRP (curated)
Strength: Strong · Confidence: High
Updated: July 2026
Indexed publications
3,000+
PubMed-indexed articles mentioning hyperemesis gravidarum, roughly 150–200 added per year this decade.
Source: PubMed query (curated)
Strength: Strong · Confidence: High
Updated: July 2026
Countries publishing
39
Countries with PubMed-indexed HG research by author affiliation; activity concentrates in six.
Source: PubMed affiliations (curated)
Strength: Moderate · Confidence: Medium
Updated: July 2026
Latest guideline movement
RCOG 2024
RCOG Green-top No. 69 updated; ACOG PB 189 (2018) remains the U.S. standard. Tracked each quarter.
Source: ACOG · RCOG · SOGC
Strength: Strong · Confidence: High
Updated: July 2026
Dashboard 01 · Clinical Impact
What HG asks of the healthcare system
Utilization evidence from published literature and federal discharge data. Trend series activate when the HCUP data connection is established — ranges below are published estimates, not live feeds.
Hospital utilization — published picture
Published estimates
Hospitalization (any)
Common
Emergency department visit
Common
Readmission after discharge
Frequent
IV hydration (any setting)
Very common
PICC line placement
Refractory HG
Enteral (tube) feeding
Refractory HG
Total parenteral nutrition
Rare · high risk
Bars indicate relative frequency among women with HG, from published cohort studies and reviews (HER Foundation registry studies; Fejzo et al.; ACOG PB 189). Escalation therapies (PICC, enteral feeding, TPN) are reserved for refractory HG — their use signals severity, not preference. Confidence: medium; utilization varies widely by setting.
Why this matters
HG is a leading cause of hospitalization in the first half of pregnancy.
Behind each admission is usually a delay: symptoms dismissed until dehydration forced the issue. Earlier treatment is the single most modifiable factor in this dashboard.
Dashboard 02 · Patient Impact
The Impact of HG Beyond the Symptoms
Published evidence exploring the physical, emotional, family, and economic impacts of Hyperemesis Gravidarum.
Where high-quality evidence exists, it is clearly identified. Where important questions remain unanswered, we transparently identify those evidence gaps rather than drawing unsupported conclusions.
Physical
DehydrationHallmark of untreated HG
Weight loss ≥5%Common diagnostic criterion
Malnutrition & electrolyte imbalanceDocumented in severe HG
Fatigue & weaknessNear-universal patient report
Oral & dental healthAcid erosion; understudied
Mobility limitationResearch needed
Mental Health
Antenatal anxietyElevated in HG cohorts
Antenatal depressionElevated in HG cohorts
Post-HG PTSD symptomsReported; few longitudinal studies
IsolationWidely reported; unmeasured
Family
Caregiver burdenResearch needed
Childcare impactResearch needed
Partner mental healthResearch needed
Employment
Work disruptionMajority report time lost
FMLA utilizationNo HG-specific series
Disability leaveNo HG-specific series
Financial impactCost-of-illness study needed
Understanding the Evidence
Each topic is assigned an evidence rating that reflects the strength of the currently available published evidence.
Strong EvidenceSupported by multiple high-quality studies or well-established clinical evidence.
Moderate EvidenceSupported by published evidence, though additional research would strengthen confidence.
Limited EvidenceSome published evidence exists, but findings remain limited, emerging, or inconsistent.
Research NeededCurrent published evidence is insufficient. Additional research is needed before evidence-based conclusions can be drawn.
Evidence evolves over time. These ratings are reviewed and updated as new high-quality research becomes available.
These ratings describe the strength of the available research, not the severity of Hyperemesis Gravidarum or the importance of a topic.
Dashboard 03 · Pregnancy Outcomes
Outcomes, stated honestly
The most sensitive numbers on this platform. Where evidence is limited — HG-attributable termination, long-term outcomes — we mark a research gap instead of publishing an unsupported statistic.
OutcomeWhat the evidence showsStatus
Live birth
With treatment, the overwhelming majority of HG pregnancies result in live birth. Treated HG is not associated with meaningfully reduced live-birth rates in most cohorts.
Published estimate
Miscarriage
Studies do not show increased miscarriage risk attributable to HG itself; some suggest lower rates, possibly reflecting robust placental hormone activity.
Published estimate
Preterm birth
Modestly elevated risk reported in severe or undertreated HG, particularly with poor weight gain; findings vary across cohorts.
Published estimate
NICU admission
Some cohorts report higher admission rates with severe HG; evidence is inconsistent and confounded by preterm birth.
Limited evidence
Birthweight
Lower mean birthweight and higher small-for-gestational-age rates associated with severe HG and pronounced maternal weight loss.
Published estimate
HG-attributable termination
Survey evidence indicates some women end wanted pregnancies because of untreatable suffering — but no reliable population-level rate exists. Reported as a research gap, not a statistic.
Research gap
Maternal outcomes
Rare but serious complications documented in case literature: Wernicke’s encephalopathy from thiamine deficiency, esophageal injury, ICU admission. Preventable with modern treatment.
Case evidence
Long-term child outcomes
Sparse, conflicting early evidence on neurodevelopment after HG exposure. Designated a priority gap.
Research gap
Reading this dashboard
With treatment, the overwhelming majority of HG pregnancies end in the birth of a healthy baby. Elevated risks appear mainly when HG is severe, prolonged, or undertreated — which is why this platform pairs every outcome statistic with a route back to treatment education in the Care Hub.
Global View
Where the world studies HG
PubMed-indexed research activity by country of author affiliation. Hover a country for detail. Trial-site and guideline-adoption layers arrive with the Phase 2 data connections.
Research Snapshot
Last Updated
August 6, 2026
Reviewed quarterly, and whenever new evidence is incorporated.
Coverage
39 Countries
Countries with at least one indexed HG publication by author affiliation.
Clinical Guidelines Reviewed
3 Guidelines
National specialty guidance currently included: ACOG, RCOG, SOGC.
Evidence Sources
PubMed
Peer-Reviewed Literature
Clinical Practice Guidelines
Research is continuously reviewed as new evidence becomes available. Dashboard metrics reflect the most current validated information available at the time of the latest update.
Dashboard 04 · Research Intelligence
The living research feed
A curated shelf of peer-reviewed publications, guidelines, and trials from PubMed, ClinicalTrials.gov, and professional societies. Updated quarterly by the THON editorial team — not a live feed.
Topic
Type
2024Guideline
Management of nausea/vomiting of pregnancy and hyperemesis gravidarum (update)
Updated UK guidance including validated severity scoring (PUQE), day-case IV hydration pathways, and mental health assessment.
RCOG Green-top Guideline No. 69UKTreatment
2023Original research
GDF15 linked to hyperemesis gravidarum causation (Fejzo et al.)
Landmark genetic and mechanistic study establishing the hormone GDF15 and maternal sensitivity to it as a central driver of HG — reframing HG as a biological, not psychological, condition.
NatureUSA / UKEtiology
2021Original research
Recurrence of hyperemesis gravidarum in a subsequent pregnancy (Nijsten et al.)
Prospective evidence that HG recurs in the majority of subsequent pregnancies — the single most important counseling statistic for women planning again.
AJOGNetherlandsOutcomes
2021Original research
Validation of the HELP score for HG severity (MacGibbon et al.)
A severity instrument capturing what PUQE misses — functioning, hydration, and quality of life — candidate instrument for the future THON registry.
BMC Pregnancy & ChildbirthUSAMental health
2019Original research
Long-term child neurodevelopment after HG exposure (Koot et al.)
Early cohort evidence on offspring outcomes — sparse, conflicting, and a designated major evidence gap.
BJOGNetherlandsOutcomes
2018Original research
GWAS implicates GDF15 and IGFBP7 in hyperemesis gravidarum (Fejzo et al.)
Genome-wide association study identifying the placenta-and-appetite genes GDF15 and IGFBP7 as HG risk loci.
Nature CommunicationsUSAEtiology
2018Guideline
ACOG Practice Bulletin No. 189: Nausea and vomiting of pregnancy
The current U.S. standard of care: stepwise treatment beginning with vitamin B6 ± doxylamine, escalating through antiemetics to IV hydration and nutrition support.
ACOG · Obstetrics & GynecologyUSATreatment
2018Original research
Psychological impact of hyperemesis gravidarum (Dean et al.)
Documents depression, anxiety, and trauma symptoms during and after HG pregnancies, and the compounding harm of feeling dismissed by care providers.
BMJ OpenUKMental health
2017Clinical trial
Early enteral tube feeding in hyperemesis gravidarum (Grooten et al.)
Randomized trial of early tube feeding — an example of the comparative-effectiveness research HG needs more of.
AJOG · MOTHER trialNetherlandsTreatment
2016Systematic review
Interventions for treating hyperemesis gravidarum: a systematic review
Evidence synthesis concluding that trial quality across HG treatments is strikingly low — a foundational entry in the Data Gap Index™.
Cochrane / JMFMUSATreatment
No entries match these filters — broaden the topic or type selection.
Feed shows 10 of 10 curated entries · Sources: PubMed, ClinicalTrials.gov, ACOG, RCOG · Curated July 2026
Signature Feature · HG Data Gap Index™
A dashboard whose product is absence
Most platforms show what is known. The Data Gap Index™ makes missing evidence as visible as existing evidence — a standing research agenda for funders and investigators.
MetricEvidence strengthConfidenceResearch priority
Hospitalizations (coded, U.S.)
Strong
High
Moderate
Publication & trial landscape
Strong
High
Moderate
True population prevalence
Moderate
Medium
Critical
Mental health burden (anxiety, depression)
Moderate
Medium
High
Recurrence in subsequent pregnancy
Moderate
Medium
High
Comparative treatment effectiveness
Limited
Low
Critical
ED visits & readmissions (national)
Limited
Low
High
PTSD after HG pregnancy
Limited
Low
High
HG-attributable termination rate
Gap
—
Critical
Cost of illness (medical + wages)
Gap
—
Critical
Caregiver & family burden
Gap
—
High
Long-term child outcomes
Gap
—
Critical
Strong evidence
Moderate evidence
Limited evidence
Major evidence gap
Data Transparency
How this platform earns trust
Where the data come from
Public, citable sources only: PubMed, ClinicalTrials.gov, NIH RePORTER, CDC natality data, AHRQ HCUP discharge data (licensed extracts), and published guidelines from ACOG, RCOG, and SOGC. No proprietary or individual-level clinical data.
Update frequency
Research feed and trial counts: quarterly editorial cycle. Federal utilization data: annually, on the source's release schedule (typically a two-year lag). Every metric shows its own "last updated" date — never assume freshness beyond it.
Evidence grading
Strong: consistent findings from large or federal datasets. Moderate: multiple peer-reviewed studies with some variation. Limited: few or small studies. Major gap: no adequate published evidence — reported as a gap, never estimated.
Known limitations
HG has no U.S. surveillance category; coded hospital data undercount women treated in outpatient or infusion settings, and undercount those never diagnosed. Prevalence definitions vary across studies. We publish these limitations beside the numbers they affect.
How THON evaluates quality
A Scientific Advisory Board triages every new source and publication. A Patient & Family Council reviews framing and language. No metric reaches this platform without a definition, source, strength rating, confidence rating, and reviewer sign-off.
Future capabilities — clearly labeled
Future capabilities will expand THON’s ability to organize evidence, surface meaningful insights, support research, and translate what we learn into better understanding and better care. These remain future concepts — each gated on ethics review, governance, and regulatory compliance before any build.
The Care Hub gives women knowledge. The HG Insights Dashboard™ gives the world proof.
Every gap on this platform is an invitation — to researchers, to funders, to health systems — to help close it.